NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report released on Monday morning,Benzinga reports. They currently have a $14.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.84 on Monday. NeuroSense Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.60. The company’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.03.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Yorkville Advisors Global LP purchased a new stake in NeuroSense Therapeutics in the fourth quarter worth $77,000. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics in the third quarter valued at $26,000. Squarepoint Ops LLC increased its position in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the period. Finally, Jane Street Group LLC bought a new position in NeuroSense Therapeutics in the 2nd quarter worth $54,000. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.